Welcome to our dedicated page for ReposiTrak SEC filings (Ticker: TRAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ReposiTrak filings document a Nevada operating company that provides SaaS-based traceability, compliance, risk management, and supply chain applications for retailers, wholesalers, suppliers, and food manufacturers. Its Form 8-K disclosures record quarterly results and earnings-call materials, cash dividend declarations, share repurchase authorizations, and material commercial or financing agreements involving its subsidiary PC Group.
Governance filings cover director appointments, committee assignments, annual meeting voting results, executive compensation advisory votes, and common-stock matters. The disclosures also describe the company's product families, public-company governance framework, capital allocation actions, and regulatory context for food safety and supply chain compliance.
ReposiTrak, Inc. reported solid third-quarter fiscal 2026 results, with revenue essentially flat at $5.9 million while profitability improved meaningfully. Total operating expenses fell 12% to $3.6 million, lifting income from operations 24% to about $2.3 million. GAAP net income was roughly $2.0 million, and diluted earnings per share were $0.10, in line with last year.
For the first nine months of fiscal 2026, revenue increased 5% to $17.7 million, operating expenses declined 4% to $11.7 million, and GAAP net income rose 6% to $5.5 million. Diluted EPS grew 9% to $0.28. The company ended the quarter with $26.4 million in cash and no bank debt, while returning capital through buybacks, preferred redemptions, and a quarterly dividend of $0.02 per share.
Management highlighted that more than 98% of revenue now comes from recurring SaaS contracts, with net margins above 30%. Strategically, ReposiTrak filed two new patents around its Touchless Traceability solution and data integrity tools, and advanced a collaboration with SPAR Group to pair its supply chain analytics with in-store execution services, aiming to extend its end-to-end food safety and merchandising platform.
ReposiTrak, Inc. reported stable results for the quarter ended March 31, 2026, with revenue of $5.9 million, down 1% year over year, and quarterly net income of $2.0 million. Higher-margin recurring subscription revenue and lower expenses lifted income from operations to $2.3 million.
For the nine months, revenue rose 5% to $17.7 million and net income reached $5.5 million, while diluted EPS increased to $0.28. The company ended the period with cash of $26.4 million, positive working capital of $26.3 million, and no bank debt.
ReposiTrak continued capital returns, including common share repurchases and ongoing redemption of its Series B preferred stock, leaving $1.72 million of preferred value outstanding. The board also declared a quarterly dividend of $0.02 per share. The company entered a new $3.0 million unsecured note receivable at an 8% rate with potential equity-linked return features.
ReposiTrak, Inc. Schedule 13G filed by Ashford Capital Management, Inc. reports beneficial ownership of 1,014,028 shares of common stock, representing 5.57% of the class based on February 17, 2026 outstanding share count. The filing states these shares are held across separate client accounts, three limited partnerships, and one commingled fund.
Handelsbanken Fonder filed an amendment to Schedule 13G/A reporting no beneficial ownership of ReposiTrak, Inc. common stock. The filing states 0 shares beneficially owned, representing 0% of the class, and affirms the filer holds ownership of 5 percent or less. The filing is signed by Emma Viotti, Managing Director with a signature date of 04/27/2026.
ReposiTrak, Inc. declared a quarterly cash dividend of $0.02 per share, or $0.08 per share annually, on its common stock. The dividend is payable on or about May 15, 2026 to stockholders of record on March 31, 2026. The company expects subsequent dividends to be paid within 45 days after each fiscal quarter end.
ReposiTrak, Inc.’s Form 4 shows an open-market sale of 7,500 shares of Common Stock at a weighted average price of $8.0596 per share. The sale was made by RK Fields Charitable 2022, LLC under a pre-arranged Rule 10b5-1 trading plan to help meet charitable commitments.
After this transaction, that LLC holds 70,000 ReposiTrak shares indirectly for Randall K. Fields. The filing also reports Fields directly owning 3,483,955 Common shares, along with additional indirect holdings, including 615,260 Common shares via Riverview Financial Corp., 333,643 via Fields Management, Inc., and related Series B Preferred Stock positions.
ReposiTrak, Inc. director James R. Gillis filed a Form 3, which is an initial statement of beneficial ownership of company securities. This filing simply establishes his status as an insider and does not report any stock purchases, sales, option exercises, or other transactions.
ReposiTrak, Inc., through its subsidiary PC Group, entered into a strategic financing arrangement with SPAR Marketing Force, Inc. via a senior unsecured promissory note of up to $4,000,000. The facility includes an initial $3,000,000 advance and an additional $1,000,000 available beginning July 17, 2026.
The note carries 8.0% annual interest, payable monthly on an interest-only basis, and matures on March 16, 2029. As part of the deal, PC Group is to receive 1,000,000 shares of SPAR Group common stock at a deemed value of $0.80 per share, with anti-dilution and price protection features.
SPAR Group, Inc. guarantees the borrower’s obligations. The agreement includes customary default triggers, after which the interest rate increases to 12.0% and PC Group can accelerate repayment.
ReposiTrak, Inc. director and CEO Randall K. Fields reported pre-planned insider sales executed by a charitable entity associated with him. RK Fields Charitable 2022, LLC sold a total of 7,500 shares of ReposiTrak common stock in open-market transactions on March 16–17, 2026 at weighted average prices slightly above $8 per share.
The filing states these sales occurred automatically under a Rule 10b5-1 trading plan adopted by Fields in his capacity as trustee of the related charitable trust to help meet charitable commitments. After these sales, that LLC held 77,500 shares. The Form 4 also shows Fields continues to hold 3,483,955 ReposiTrak common shares directly, plus additional indirect holdings through Riverview Financial Corp., his spouse, and Fields Management, Inc.
ReposiTrak, Inc. filed a current report describing the return of James R. Gillis to its Board of Directors, effective March 13, 2026. He will also serve on the Audit and Compensation Committees. The Board determined that he qualifies as an independent director under New York Stock Exchange listing standards.
Gillis is CEO of Gillis & Associates, Inc., an M&A advisory firm, and previously served on ReposiTrak’s board from 2008 to 2015. He has more than 35 years of experience in retail supply chain management, mergers and acquisitions, and organizational growth, and currently holds multiple other board and advisory roles.